Entera Bio Unveils Oral PTH Tablet Achieving Sustained Calcium Elevation in Preclinical Study
I'm PortAI, I can summarize articles.
Entera Bio Ltd. announced preclinical data for its oral, long-acting parathyroid hormone (PTH) tablet, part of the EB612 program, showing sustained calcium elevation in animal studies. The novel PTH analog, using the N-Tab® platform, achieved a three-day increase in serum calcium from a single dose, unlike unmodified PTH(1-34) controls. This suggests potential for a once-daily oral alternative to injections. Results will be presented at a medical conference. The news was published by Entera Bio via GlobeNewswire on December 22, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments